Glaucoma Following Surgery study: Topical infliximab
Official title Topical Infliximab in Eyes With Penetrating Keratoplasty
ClinicalTrials.gov ID: NCT05180994
What this study is testing
What is Topical infliximab?
Investigational eye drops being studied to prevent glaucoma after penetrating keratoplasty surgery. is designed to block tumor necrosis factor‑alpha (TNF‑α).
Also referred to as Remicade.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study wants to find out if using infliximab eye drops after a cornea transplant is safe and if it can reduce the risk of developing glaucoma.
- Who it's for
- It is looking for people who have had a cornea transplant and are at risk of glaucoma after the surgery.
- What's involved
- Participants will use the infliximab eye drops as directed, attend scheduled clinic visits, and have eye tests to monitor safety and eye pressure.
- Time commitment
- The study lasts several months, with regular follow‑up visits at the clinic to check eye health and record any side effects.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Age between 18 and 80 years;
- First corneal transplant surgery;
- Capable of providing informed consent;
- Capable of administering eye medication or access to a caregiver able and willing to administer the eye medication for the patient.
You likely can't join if
- Active ocular infection;
- Past corneal transplant (any technique);
- Advanced glaucoma or macular disease;
- Active or latent systemic infection (tuberculosis, histoplasmosis, coccidioidomycosis, cytomegalovirus, pneumocystis, aspergillosis or hepatitis B);
- Malignancy diagnosed in the past 5 years (any kind);
- Demyelinating disease;
See the full eligibility criteria
- Age between 18 and 80 years;
- First corneal transplant surgery;
- Capable of providing informed consent;
- Capable of administering eye medication or access to a caregiver able and willing to administer the eye medication for the patient.
- Active ocular infection;
- Past corneal transplant (any technique);
- Advanced glaucoma or macular disease;
- Active or latent systemic infection (tuberculosis, histoplasmosis, coccidioidomycosis, cytomegalovirus, pneumocystis, aspergillosis or hepatitis B);
- Malignancy diagnosed in the past 5 years (any kind);
- Demyelinating disease;
- History or current diabetes mellitus (controlled or uncontrolled) or heart failure (New York Heart Association class III or IV);
- Pregnancy or breastfeeding;
- Allergy to infliximab or to a compound of its topical formulation;
- Significant anomaly of complete blood count or hepatic enzymes;
- Current or anterior use of anti-TNF-α medication or other anti-inflammatory biologics.
The study team makes the final eligibility decision.
Where it is enrolling
- Montreal, Quebec, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Montreal, Quebec, Canada. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.